N/A N=164 Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Catheter System Feasibility Clinical Trial
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
N/A N=103 Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants
N/A N=46 Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation
Chronic Kidney Disease · Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Mean Scores of a Questionnaire Evaluating Patient Confidence in Navigating Vascular Access Care Pre- to Post-program Implementation — 8.0; 8.7 score on a scale — p=0.20
N/A N=436 Hemodialysis Access Surveillance Evaluation Study
Hemodialysis Access · Thrombosis
Primary: Hemodialysis Access Thrombosis Rate — 0.122; 0.227 thrombotic events per patient
N/A N=330 IN.PACT™ AV Access IDE Study
Arteriovenous Fistula Stenosis · Arteriovenous Fistula Occlusion · Arteriovenous Fistula
Primary: Target Lesion Primary Patency Rate Through 6 Months — 125; 88 Participants — p=<0.001
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
N/A N=44 Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
Kidney Diseases
Primary: Feasibility- Eligibility for Randomization — 54 Participants
N/A N=46 Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)
Kidney Diseases
Primary: Vein Diameter — 1.692; 2.100 millimeters — p=0.012
N/A N=16 Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Subclavian Steal
Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants
N/A N=72 Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
Renal Failure Chronic Requiring Hemodialysis
Primary: Percentage of Patients With Primary Patency — 48.2; 47.0; 30.6; 34.8 percentage of participants patent
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
Phase 3 N=138 Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 83.6 percentage of participants
N/A N=10 Coronal Mode Ultrasound Guided Hemodialysis Cannulation: Comparison With Standard Cannulation Technique
Arteriovenous Fistula, Cannulation
Primary: Infiltration Due to Dialysis Access Cannulation — 5; 7 infiltration events
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
Phase 3 N=311 A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)
Chronic Kidney Disease
Primary: Time to AVF Primary Unassisted Patency — 214; 171 Days — p=0.254
N/A N=33 Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer
Chronic Kidney Failure
Primary: Ease of Use: Priming Blood Side — 139; 13; 13; 80 Number of Dialyzers
N/A N=1,431 Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)
Kidney Failure · End Stage Renal Disease · Hypotension
Primary: Dialysis Session Stability — 0.202; 0.199; 0.172; 0.182 Proportion of sessions
N/A N=100 VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC
Renal Failure Chronic Requiring Hemodialysis · Chronic Renal Insufficiency
Primary: Primary Patency - Intervention-free Interval (Measured in Weeks) — 89.1; 95.5; 79.4; 87.2 percentage of primary patency
N/A N=599 Dialysis Catheter Comparative Clinical Trial
End Stage Renal Disease
Primary: First Catheter Induced Complication — 78; 77 percentage of participants
Phase 3 N=223 A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
Dysfunctional Hemodialysis Catheters
Primary: Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 — 34.1 Percentage of participants
Phase 2 N=64 An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
Arteriovenous Fistula
Primary: Percentage of Participants With Arteriovenous Fistula (AVF) Maturation by Week 12 Visit Based on Hemodialysis or Color-flow Doppler Ultrasound (CDUS) And Vascular Access…
Phase 3 N=54 Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
End Stage Renal Disease · AV Fistula · Kidney Failure
Primary: Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis — 49 participants
N/A N=209 Cohort Study on A Following-up System of Native Arteriovenous Fistulae
Arteriovenous Fistulae
Primary: Number of Participants With Fistula Failure — 11; 15 Participants
N/A N=32 everlinQ Endovascular Access System Enhancements (EASE) Study
Chronic Kidney Diseases
Primary: Number of Participants With Protocol-Defined endoAVF Maturation — 29 Participants
Phase 2 N=30 Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis
Renal Failure · End Stage Renal Disease · Vascular Access
Primary: Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAV — 0 participants
N/A N=144 VasQ External Support for Arteriovenous Fistula
Arterio-Venous Fistula · ESRD · Steal Syndrome
Primary: Primary Patency of AVF — 88 Participants
Phase 4 N=17 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Arteriovenous Fistula
Primary: Clotting TIme — 6; 8 minutes
N/A N=14 Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis
Renal Failure
Primary: Feasibility of Participant Recruitment and Site Coordination — 8; 6 Participants
Phase 4 N=309 20070360 Incident Dialysis
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001